Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UARK 2006-15: A phase III randomized study of tandem transplants with or without bortezomib (Velcade) and thalidomide (Thalomid) to evaluate its effect on response rate and durability of response in multiple myeloma patients.

Next Previous
X
Search
Trial Profile

UARK 2006-15: A phase III randomized study of tandem transplants with or without bortezomib (Velcade) and thalidomide (Thalomid) to evaluate its effect on response rate and durability of response in multiple myeloma patients.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jun 2011 Planned End Date changed from 1 Dec 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Nov 2010 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top